Yesim Dargaud
机构: Professeur de médecine, Université Lyon 1
每年引用次数
引用次数
引用: 5,543
H-指数: 39
I10-指数 : 79
出版物: 264
Genotyping might help therapeutic decision‐making in patients with von Willebrand disease type 2 B
L. Rugeri , M. Fretigny , Y. Dargaud , C. Nougier
Haemophilia 22 ( 5)
2
2016
Individualized PK-based prophylaxis in severe haemophilia.
Y. Dargaud , X. Delavenne , D.P. Hart , S. Meunier
Haemophilia 24 3 -17
15
2018
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A.
Y. Dargaud , C. Negrier , L. Rusen , J. Windyga
Haemophilia 24 ( 4) 619 -627
6
2018
Le déficit acquis en facteur V : une pathologie hémorragique rare à manifestations cliniques variables
M. Alcantara , S. Ducastelle , L. Rugeri , Y. Dargaud
Revue de Médecine Interne 32 ( 5)
5
2011
Haemophilia and thrombophilia: an unexpected association!
Y. Dargaud , S. Meunier , C. Negrier
Haemophilia 10 ( 4) 319 -326
58
2004
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Y. Dargaud , A. Lienhart , S. Meunier , O. Hequet
Haemophilia 11 ( 5) 552 -558
79
2005
Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency
S. Le Quellec , A. Desjonqueres , L. Rugeri , H. Desmurs Clavel
Thrombosis Journal 16 ( 1) 6 -6
4
2018
Score de prédiction de risque de maladie thromboembolique veineuse en milieu obstétrical
Y. Dargaud
Journal Des Maladies Vasculaires 37 ( 2) 70
2012
Thrombin-generating capacity in patients with von Willebrand’s disease
L. Rugeri , S. Beguin , C. Hemker , J.-C. Bordet
Haematologica 92 ( 12) 1639 -1646
39
2007
Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism
Yesim G. Dargaud , Lucia Rugeri , Chloe Fleury , Helene Desmurs Clavel
Blood 126 ( 23) 889 -889
1
2015
Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A
Yesim G. Dargaud , Robert Klamroth , Luminita Rusen , Jerzy Windyga
Blood 128 ( 22) 1410 -1410
2016
The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?
Yesim G. Dargaud , Marc Fouassier , Sophie Ducastelle , Philippe Moreau
Blood 124 ( 21) 2037 -2037
2014
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A
M. NINIVAGGI , Y. DARGAUD , R. Van OERLE , B. De LAAT
Journal of Thrombosis and Haemostasis 9 ( 8) 1549 -1555
19
2011
Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.
J. L. PLANTIER , V. ROLLI , C. DUCASSE , Y. DARGAUD
Journal of Thrombosis and Haemostasis 8 ( 2) 286 -293
16
2010
Mechanisms and monitoring of bypassing agent therapy
M. HOFFMAN , Y. DARGAUD
Journal of Thrombosis and Haemostasis 10 ( 8) 1478 -1485
75
2012
Basic aspects of bypassing agents
C. NEGRIER , Y. DARGAUD , J. C. BORDET
Haemophilia 12 48 -53
32
2006
Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study
Y. DARGAUD , H. DESMURS-CLAVEL , S. MARIN , J. C. BORDET
Journal of Thrombosis and Haemostasis 6 ( 6) 962 -968
21
2008
Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor.
Y. DARGAUD , R. LUDDINGTON , T. P. BAGLIN
Journal of Thrombosis and Haemostasis 4 ( 5) 1160 -1161
42
2006
New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.
Y. DARGAUD , T. LAMBERT , M. TROSSAERT
Haemophilia 14 20 -27
28
2008